---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031252"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T09:59:35.532405+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dare Bioscience Q2 cash $16.4M; Ovaprene Phase 3 enrolling; Sildenafil Cream awaits FDA feedback

## Summary
- Cash and equivalents $16.4M at June 30, 2024; received $22M non-dilutive royalty financing from XOMA in April 2024.
- G&A expenses $2.4M, down 17% YoY; R&D expenses $4.9M, down 19% YoY.
- Ovaprene Phase 3 contraceptive study recruiting at 20 U.S. sites; ~125 women expected to complete 6 months by Q2 2025.
- Sildenafil Cream Phase 3 design pending additional FDA feedback; each Phase 3 study estimated at ~$15M.
- Total grants received for DARE-LARC1 now ~$29.3M; pipeline includes DARE-HRT1 in development.

## SEC filing metadata
- accession: 0001493152-24-031252
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224031252/0001493152-24-031252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224031252/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031252
- JSON: https://secwatch.observer/filing/0001493152-24-031252.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031252.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.